What's Happening?
Surf Therapeutics, based in Austin, Texas, has announced positive results from its first-in-human study and secured additional funding, bringing its total to $6 million. The company is developing non-invasive ultrasound neuromodulation therapies to treat
immune-mediated diseases. The recent study involved 14 participants with inflammatory arthritis and demonstrated significant reductions in pro-inflammatory cytokines without device-related adverse events. This success has led to the initiation of a clinical study for rheumatoid arthritis, with patient enrollment underway in the Dallas–Fort Worth area. The funding will support further clinical trials and the development of a scalable, at-home therapy platform.
Why It's Important?
The advancement of Surf Therapeutics' non-invasive therapy represents a significant step forward in the treatment of autoimmune diseases like rheumatoid arthritis. By reducing inflammation without the need for pharmaceuticals or invasive procedures, this technology could offer a safer, more accessible treatment option for patients. The successful funding round and positive study results highlight the potential of ultrasound neuromodulation as a viable alternative to traditional therapies, which often come with significant side effects. This development could lead to broader adoption of non-invasive treatments, improving quality of life for patients and reducing healthcare costs associated with chronic autoimmune conditions.
